Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
53
SNBIF Quote, Financials, Valuation and Earnings
Last price:
$23.00
Seasonality move
:
24.46%
Day range:
$23.00 - $23.00
52-week range:
$4.65 - $23.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
279.12x
P/B ratio:
192.65x
Volume:
--
Avg. volume:
--
1-year change:
288.51%
Market cap:
$1.7B
Revenue:
--
EPS (TTM):
-$0.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNBIF
SanBio Co., Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 2.78% | -- | $17.76 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNBIF
SanBio Co., Ltd.
|
$23.00 | -- | $1.7B | -- | $0.00 | 0% | 279.12x |
|
HLOSF
Healios KK
|
$2.50 | -- | $288.5M | -- | $0.00 | 0% | 392.54x |
|
PPTDF
PeptiDream Inc.
|
$10.95 | -- | $1.4B | 13.79x | $0.00 | 0% | 11.79x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.00 | -- | $452.5M | -- | $0.00 | 0% | 2.34x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.18 | $17.76 | $44.8B | 179.95x | $0.32 | 4.66% | 1.53x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNBIF
SanBio Co., Ltd.
|
51.18% | -1.897 | 0.88% | 5.55x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNBIF
SanBio Co., Ltd.
|
-$13.3K | -$6.1M | -158.31% | -251.37% | -- | -$10.9M |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
SanBio Co., Ltd. vs. Competitors
-
Which has Higher Returns SNBIF or HLOSF?
Healios KK has a net margin of -- compared to SanBio Co., Ltd.'s net margin of -9751.87%. SanBio Co., Ltd.'s return on equity of -251.37% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital SNBIFSanBio Co., Ltd.-- -$0.04 $17.6M HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About SNBIF or HLOSF?
SanBio Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio Co., Ltd. has higher upside potential than Healios KK, analysts believe SanBio Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings SNBIFSanBio Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is SNBIF or HLOSF More Risky?
SanBio Co., Ltd. has a beta of -0.525, which suggesting that the stock is 152.546% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock SNBIF or HLOSF?
SanBio Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio Co., Ltd. pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNBIF or HLOSF?
SanBio Co., Ltd. quarterly revenues are --, which are smaller than Healios KK quarterly revenues of $128.8K. SanBio Co., Ltd.'s net income of -$3.2M is lower than Healios KK's net income of $3.8M. Notably, SanBio Co., Ltd.'s price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio Co., Ltd. is 279.12x versus 392.54x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNBIFSanBio Co., Ltd.279.12x -- -- -$3.2M HLOSFHealios KK392.54x -- $128.8K $3.8M
-
Which has Higher Returns SNBIF or PPTDF?
PeptiDream Inc. has a net margin of -- compared to SanBio Co., Ltd.'s net margin of -25.38%. SanBio Co., Ltd.'s return on equity of -251.37% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital SNBIFSanBio Co., Ltd.-- -$0.04 $17.6M PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About SNBIF or PPTDF?
SanBio Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe SanBio Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNBIFSanBio Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is SNBIF or PPTDF More Risky?
SanBio Co., Ltd. has a beta of -0.525, which suggesting that the stock is 152.546% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock SNBIF or PPTDF?
SanBio Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio Co., Ltd. pays -- of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNBIF or PPTDF?
SanBio Co., Ltd. quarterly revenues are --, which are smaller than PeptiDream Inc. quarterly revenues of $29.3M. SanBio Co., Ltd.'s net income of -$3.2M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, SanBio Co., Ltd.'s price-to-earnings ratio is -- while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio Co., Ltd. is 279.12x versus 11.79x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNBIFSanBio Co., Ltd.279.12x -- -- -$3.2M PPTDFPeptiDream Inc.11.79x 13.79x $29.3M -$7.4M
-
Which has Higher Returns SNBIF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of -- compared to SanBio Co., Ltd.'s net margin of -24.76%. SanBio Co., Ltd.'s return on equity of -251.37% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital SNBIFSanBio Co., Ltd.-- -$0.04 $17.6M SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About SNBIF or SOLTF?
SanBio Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe SanBio Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SNBIFSanBio Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is SNBIF or SOLTF More Risky?
SanBio Co., Ltd. has a beta of -0.525, which suggesting that the stock is 152.546% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock SNBIF or SOLTF?
SanBio Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio Co., Ltd. pays -- of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNBIF or SOLTF?
SanBio Co., Ltd. quarterly revenues are --, which are smaller than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. SanBio Co., Ltd.'s net income of -$3.2M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, SanBio Co., Ltd.'s price-to-earnings ratio is -- while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio Co., Ltd. is 279.12x versus 2.34x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNBIFSanBio Co., Ltd.279.12x -- -- -$3.2M SOLTFNxera Pharma Co., Ltd.2.34x -- $45.8M -$11.3M
-
Which has Higher Returns SNBIF or STMM?
Stemcell Holdings, Inc. has a net margin of -- compared to SanBio Co., Ltd.'s net margin of --. SanBio Co., Ltd.'s return on equity of -251.37% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNBIFSanBio Co., Ltd.-- -$0.04 $17.6M STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About SNBIF or STMM?
SanBio Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe SanBio Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNBIFSanBio Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is SNBIF or STMM More Risky?
SanBio Co., Ltd. has a beta of -0.525, which suggesting that the stock is 152.546% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SNBIF or STMM?
SanBio Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio Co., Ltd. pays -- of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNBIF or STMM?
SanBio Co., Ltd. quarterly revenues are --, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. SanBio Co., Ltd.'s net income of -$3.2M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, SanBio Co., Ltd.'s price-to-earnings ratio is -- while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio Co., Ltd. is 279.12x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNBIFSanBio Co., Ltd.279.12x -- -- -$3.2M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns SNBIF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of -- compared to SanBio Co., Ltd.'s net margin of -1.05%. SanBio Co., Ltd.'s return on equity of -251.37% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital SNBIFSanBio Co., Ltd.-- -$0.04 $17.6M TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About SNBIF or TAK?
SanBio Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 25.04%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than SanBio Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than SanBio Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SNBIFSanBio Co., Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is SNBIF or TAK More Risky?
SanBio Co., Ltd. has a beta of -0.525, which suggesting that the stock is 152.546% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock SNBIF or TAK?
SanBio Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.66% to investors and pays a quarterly dividend of $0.32 per share. SanBio Co., Ltd. pays -- of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend.
-
Which has Better Financial Ratios SNBIF or TAK?
SanBio Co., Ltd. quarterly revenues are --, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. SanBio Co., Ltd.'s net income of -$3.2M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, SanBio Co., Ltd.'s price-to-earnings ratio is -- while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 179.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio Co., Ltd. is 279.12x versus 1.53x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNBIFSanBio Co., Ltd.279.12x -- -- -$3.2M TAKTakeda Pharmaceutical Co., Ltd.1.53x 179.95x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 48.08% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 6.66% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 6.48% over the past day.
